Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in profits, according to a report from the Federal Trade Commission, or FTC.
The document, which evaluated the prescription drug middlemen industry from 2017 to 2022, described “a growing profit center” in these massive markups.
The report revealed that the three largest pharmacy benefit managers (PBMs) in the United States — Optum (a subsidiary of UnitedHealth Group), Caremark Rx (a subsidiary of CVS Health Corporation, which